sun pharma (CreditSuisse) Strong chronic franchise continues to drive outperformance; expect FY12 growth guidance of 18%

Strongest domestic performance across peers; Strong Taro performance; ex Taro exports weaker
Date Rating Target Price Recommendation Price Broker house
30 May 2011 outperform 515 445 CreditSuisse Report

No comments:

Post a Comment